Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unpacking Lysosomal Storage: New Insights Drive Parkinson’s Drug Development

This article was originally published in Start Up

Executive Summary

Investors and dealmakers are using recent discoveries about convergences between Gaucher’s disease and Parkinson’s in the lysosome to generate new therapeutic programs. Start-up Lysosomal Therapeutics thinks that the rare disorder can serve as a model system for developing new drugs to increase lysosomal function as a way to treat Parkinson’s disease and possibly other neurodegenerative disorders.

You may also be interested in...

Will Yeast Lead The Way To Parkinson’s Disease Drugs? An Interview With Tony Coles Of Yumanity Therapeutics

The duo behind Yumanity brings to it multiple successes measured by basic science discoveries, new drugs for patients, and billions made for investors. Can they do it again with their novel approach for discovering neurodegenerative disease drugs?

Still Hopeful About Migalastat, Amicus Also Pursuing Optimized Enzyme Replacement Therapies

Amicus’ most promising candidate would improve upon Sanofi/Genzyme’s Pompe disease drug Lumizyme, but closer to the clinic is a program to combine Fabry disease candidate migalastat with an enzyme replacement therapy obtained in last year’s buyout of Callidus.

With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts